Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
10909335 | Leukemia Research | 2009 | 4 Pages |
Abstract
The patients with early and continuously increased MCV level irrespective of anemia achieved higher CCR after 12 months of imatinib therapy than patients with non-CCR (p = 0.011). When the value was compared with low Sokal score, elevated MCV was independent predictor of CCR (RR = 12.925, p = 0.002 vs. RR = 35.445, p < 0.001). Furthermore, the patients with early and continuously increased MCV level had a higher probability of maintaining CCR than non-increased level (p = 0.019). Increased MCV level was surrogate marker of achievement and durability to CCR for early CP-CML patients in the present study.
Related Topics
Life Sciences
Biochemistry, Genetics and Molecular Biology
Cancer Research
Authors
Moo-Kon Song, Joo-Seop Chung, Young-Mi Seol, Seong-Geun Kim, Ho-Jin Shin, Young-Jin Choi, Goon-Jae Cho,